Esketamine Nasal Spray for Depression
Customize your policy alerts
Sign up for Bluecross Idaho Policy MP 5.01.34 alerts
Get alerted when Policy MP 5.01.34 changes without checking for updates manually.
Monitor payer policy activity
Medical-necessity and prior-authorization criteria for esketamine nasal spray in adults with treatment-resistant depression or major depressive disorder with acute suicidal ideation or behavior, including FDA-label-consistent use and Spravato REMS compliance.
The policy was updated to include use of esketamine nasal spray as monotherapy for treatment-resistant depression.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.